Maya Barake1,2, Asma Arabi3,4, Nancy Nakhoul3,5, Ghada El-Hajj Fuleihan3,4, Sarah El Ghandour6, Anne Klibanski7, Nicholas A Tritos7. 1. Scholars in HeAlth Research Program, American University of Beirut, Beirut, Lebanon. maya.barake@cmc.com.lb. 2. Clemenceau Medical Center, Beirut, Lebanon. maya.barake@cmc.com.lb. 3. Scholars in HeAlth Research Program, American University of Beirut, Beirut, Lebanon. 4. Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Diseases, American University of Beirut, Beirut, Lebanon. 5. Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. 6. Bareen International Hospital, Abu Dhabi, United Arab Emirates. 7. Massacchusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
PURPOSE: In adults, growth hormone deficiency (GHD) has been associated with low bone mineral density (BMD), an effect counteracted by growth hormone (GH) replacement. Whether GH is beneficial in adults with age-related bone loss and without hypopituitarism is unclear. METHODS: We conducted a systematic literature search using Medline, Embase and the Cochrane Register of Controlled Trials. We extracted and analyzed data according to the bone outcome included [bone mineral content (BMC), BMD, and bone biomarker, fracture risk]. We performed a meta-analysis when possible. RESULTS: We included eight studies. Seven randomized 272 post-menopausal women, 61-69 years, to GH or control, for 6-24 months, and the eighth was an extension trial. Except for one study, all women received concurrent osteoporosis therapies. There was no significant effect of GH, as compared to control, on BMD at the lumbar spine (Weighted mean difference WMD = -0.01 [-0.04, 0.02]), total hip (WMD = 0 [-0.05, 0.06]) or femoral neck (WMD = 0 [-0.03, 0.04]). Similarly, no effect was seen on BMC. GH significantly increased the bone formation marker procollagen type-I carboxy-terminal propeptide (PICP) (WMD = 14.03 [2.68, 25.38]). GH resulted in a trend for increase in osteocalcin and in bone resorption markers. Patients who received GH had a significant decrease in fracture risk as compared to control (RR = 0.63 [0.46, 0.87]). Reported adverse events were not major, mostly related to fluid retention. CONCLUSION: GH may not improve bone density in women with age-related bone loss but may decrease fracture risk. Larger studies of longer duration are needed to further explore these findings in both genders, and to investigate the effect of GH on bone quality.
PURPOSE: In adults, growth hormone deficiency (GHD) has been associated with low bone mineral density (BMD), an effect counteracted by growth hormone (GH) replacement. Whether GH is beneficial in adults with age-related bone loss and without hypopituitarism is unclear. METHODS: We conducted a systematic literature search using Medline, Embase and the Cochrane Register of Controlled Trials. We extracted and analyzed data according to the bone outcome included [bone mineral content (BMC), BMD, and bone biomarker, fracture risk]. We performed a meta-analysis when possible. RESULTS: We included eight studies. Seven randomized 272 post-menopausal women, 61-69 years, to GH or control, for 6-24 months, and the eighth was an extension trial. Except for one study, all women received concurrent osteoporosis therapies. There was no significant effect of GH, as compared to control, on BMD at the lumbar spine (Weighted mean difference WMD = -0.01 [-0.04, 0.02]), total hip (WMD = 0 [-0.05, 0.06]) or femoral neck (WMD = 0 [-0.03, 0.04]). Similarly, no effect was seen on BMC. GH significantly increased the bone formation marker procollagen type-I carboxy-terminal propeptide (PICP) (WMD = 14.03 [2.68, 25.38]). GH resulted in a trend for increase in osteocalcin and in bone resorption markers. Patients who received GH had a significant decrease in fracture risk as compared to control (RR = 0.63 [0.46, 0.87]). Reported adverse events were not major, mostly related to fluid retention. CONCLUSION: GH may not improve bone density in women with age-related bone loss but may decrease fracture risk. Larger studies of longer duration are needed to further explore these findings in both genders, and to investigate the effect of GH on bone quality.
Entities:
Keywords:
Bone mineral density; Fracture; Growth hormone; Meta-analysis; Osteoporosis
Authors: Hau Liu; Dena M Bravata; Ingram Olkin; Smita Nayak; Brian Roberts; Alan M Garber; Andrew R Hoffman Journal: Ann Intern Med Date: 2007-01-16 Impact factor: 25.391
Authors: A Cranney; P Tugwell; S Cummings; P Sambrook; J Adachi; A J Silman; W J Gillespie; D T Felson; B Shea; G Wells Journal: J Rheumatol Date: 1997-06 Impact factor: 4.666
Authors: C Wüster; R Abs; B A Bengtsson; H Bennmarker; U Feldt-Rasmussen; E Hernberg-Ståhl; J P Monson; B Westberg; P Wilton Journal: J Bone Miner Res Date: 2001-02 Impact factor: 6.741
Authors: Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-06 Impact factor: 5.958
Authors: D B Allen; P Backeljauw; M Bidlingmaier; B M K Biller; M Boguszewski; P Burman; G Butler; K Chihara; J Christiansen; S Cianfarani; P Clayton; D Clemmons; P Cohen; F Darendeliler; C Deal; D Dunger; E M Erfurth; J S Fuqua; A Grimberg; M Haymond; C Higham; K Ho; A R Hoffman; A Hokken-Koelega; G Johannsson; A Juul; J Kopchick; P Lee; M Pollak; S Radovick; L Robison; R Rosenfeld; R J Ross; L Savendahl; P Saenger; H T Sorensen; K Stochholm; C Strasburger; A Swerdlow; M Thorner Journal: Eur J Endocrinol Date: 2015-11-12 Impact factor: 6.664
Authors: Selveta S van Santen; Daniel S Olsson; Marry M van den Heuvel-Eibrink; Mark Wijnen; Casper Hammarstrand; Joseph A M J L Janssen; Gudmundur Johansson; Aart J van der Lely; Sebastian J C M M Neggers Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958